Reach out to learn more about how our Asset Strategists can customize an integrated solution for your unique asset.
Let's talk
Syneos One is the most powerful expression of our Biopharmaceutical Acceleration Model (BAM). A fully integrated, insights-driven product development methodology. This proprietary methodology provides a unique combination of asset strategy and execution to maximize value from early concept through to commercialization.
Syneos One
Let's talk
Adopting a Fully Integrated End-to-End Product Development Methodology to Maximize Asset Value
White Paper
READ MORE
Speeding Site Start Up with Optimized Processes
White Paper
READ MORE
See How Agile Practices Have the Potential to Solve Some of Biopharma's Biggest Pain Points
Report
READ MORE
To Spend or Not to Spend: Investing for Launch Success as an Emerging Company
report
READ MORE
Understanding which Real-World Research Design is Best
White Paper
READ MORE
An Integrated Development Plan in Rare & Orphan Medicinal Products (OMPs)
REport
Read MOre
One team creates and executes an integrated plan that delivers:
Integrated real world and commercial insights early into clinical strategy
Increased predictive enrollment forecast modeling/ global investigator transparency
Harmonized case for product approval, reimbursement and use
Our Latest Insights
Meet Our Asset Strategists
Head Asset Team
Commercial Strategy SME
US
Amanda Biedess
Asset Lead
Market Access SME
UK
Doug Niven
Asset Lead
Product Development SME
US
Jim Brigaitis
Asset Lead
Rare, Orphan & RWE SME
DE
Maryna Kolochavina
Asset Lead
Early Phase Clinical SME
FR
Samira Shaimi
Asset Lead
Digital SME
UK
Skye Hodson
Asset Lead
Product Dev & Onc SME
US
Toral Untz
Asset Lead
Rare, Orphan & Gen Med SME
US
Valerie Anderson
Reduced Risk
Reduced Risk
Increased Speed to Market
Faster patient enrollment
Stronger case for market access
Reduced time-to-approval barriers through integrated early planning, design and execution
Operational Efficiency
'Easy to work with' single point of contact across integrated development plan
Constant data and insight sharing across clinical and commercial for greater efficiency
Agile technology & innovation to continually optimize processes
Increased Speed to Market
Operational
Efficiency
One Team Providing Fully Integrated Product Development Solutions to Maximize Asset Value
Dynamic Assembly®
Trusted Process
®
Clinical Solutions
Commercial Solutions
Syneos One®
Real World Evidence
Highly adept at closing gaps and creating time- saving efficiencies, Syneos One Asset Strategists ensure that data, knowledge and insights move seamlessly back and forth along the continuum informing and improving each step along the way.
With deep expertise across the entire spectrum of clinical development to full commercialization, our Asset Strategists are able to coordinate the right teams at the right time to develop fully integrated, customized solutions that help to maximize an asset’s Net Present Value.
Our Syneos One
Asset Strategists
Single point of contact leading the way from clinical development to full commercialization
Designing and executing relevant, effective and efficient solutions that speed clinical development and commercial success
Harnessing the Broad Power of the Clinical to Commercial Continuum "As One"
Click through the different phases to explore
Increased
Net Present
Value
Clinical
COMMERCIAL
Designing and executing relevant, effective and efficient solutions that speed clinical development and commercial success
Best experienced on desktop
®
®
One team creates and executes an integrated plan that delivers:
Advisory & Strategic Consulting Services
Advisory & Strategic Consulting Services
Advisory & Strategic Consulting Services
Adopting a Fully Integrated End-to-End Product Development Methodology to Maximize Asset Value
Sales &
Marketing
Market
Access
Regulatory
& Medical Affairs
Real World Evidence
Clinical
Maturity
Growth
Product Launch
Phase IIb/III
Phase IIa
Phase I
Powered by our Biopharmaceutical Acceleration Model
Product Development Lifecycle
SALES REPS - TELE DETAILING - TRAINING - SALES OPS
BRAND & COMPANY PUBLIC RELATIONS - ADVERTISING - DATA SCIENCE - DIGITAL - SOCIAL MEDIA
NAMING & BRANDING ASSETS & STUDIES
COMMERCIAL STRATEGY - PORTFOLIO STRATEGY - CORPORATE DEVELOPMENT
ACCESS ACCOUNT MANAGERS, FIELD REIMBURSEMENT SPECIALISTS, TRAINING AND DEPLOYMENT
RISK MITIGATION - REPUTATION MANAGEMENT - PUBLIC AFFAIRS - POLICY & ADVOCACY - STAKEHOLDER ENGAGEMENT
MARKET ACCESS - PRICING & CONTRACTING STRATEGY - HEALTH ECONOMIC MODELS - PAYER COMMUNICATIONS
NURSE EDUCATORS
MEDICAL FIELD TEAM RECRUITMENT, TRAINING & DEPLOYMENT
RISK EVALUATION AND MITIGATION AND EDUCATION
MEDICAL STRATEGY - EVIDENCE GENERATION - MEDICAL COMMS - CONGRESSES - DISEASE AWARENESS - STAKEHOLDER ENGAGEMENT - TRAINING & EDUCATION
REGULATORY STRATEGY, SUBMISSIONS & OPERATIONS
RWE LABEL EXTENSION & VALUE-BASED CONTRACTING
RWD CLINICAL TRIAL DESIGN - RWD REGULATORY SUBMISSIONS
PHASE IIa - III CLINICAL DEVELOPMENT
BIOANALYTICS & BIOMARKER SOLUTIONS
PHASE I PROOF OF CONCEPT DEVELOPMENT
PHASE I CLINICAL DEVELOPMENT
COMMERCIAL
Clinical
Designing and executing relevant, effective and efficient solutions that speed clinical development and commercial success
Harnessing the Broad Power of the Clinical to Commercial Continuum "As One"
Phase I
Phase IIa
Phase IIb/III
Maturity
Growth
Product Launch
Click through the different phases to explore
Syneos One is the most powerful expression of our Biopharmaceutical Acceleration Model (BAM). A fully integrated, insights-driven product development methodology. This proprietary methodology provides a unique combination of asset strategy and execution to maximize value from early concept through to commercialization.
Syneos One
Phase I
Phase IIa
Phase IIb/III
®
Learn more about The Syneos One ADAPT Diagnostic Tool in Rare and Orphan Diseases
®
Accelerating Progress for Patients
Accelerating Progress for Patients
Let's talk
Accelerating Progress for Patients